glucosidase alfa
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pompe Disease
Conditions
Pompe Disease
Trial Timeline
Jun 1, 2016 → Dec 31, 2020
NCT ID
NCT02824068About glucosidase alfa
glucosidase alfa is a pre-clinical stage product being developed by Sanofi for Pompe Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02824068. Target conditions include Pompe Disease.
What happened to similar drugs?
10 of 17 similar drugs in Pompe Disease were approved
Approved (10) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02824068 | Pre-clinical | Completed |
Competing Products
20 competing products in Pompe Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| S-606001 + Placebo | Shionogi | Phase 2 | 42 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| GZ402666 | Sanofi | Phase 1 | 29 |
| alglucosidase alfa + Placebo | Sanofi | Phase 3 | 40 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| Alglucosidase alfa | Sanofi | Approved | 35 |
| Avalglucosidase Alfa | Sanofi | Phase 2 | 35 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| Myozyme | Sanofi | Phase 3 | 40 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| alglucosidase alfa | Sanofi | Pre-clinical | 26 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 3 | 40 |
| Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa) | Sanofi | Approved | 35 |
| ALGLUCOSIDASE ALFA | Sanofi | Approved | 43 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 35 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 2 | 39 |
| Myozyme | Sanofi | Phase 2 | 35 |
| Myozyme | Sanofi | Phase 2 | 35 |
| recombinant human acid alpha-glucosidase (rhGAA) | Sanofi | Phase 2 | 35 |
| Alglucosidase Alfa + Methotrexate + Rituximab | Sanofi | Approved | 43 |